Morepen Labs' Facility Clears USFDA Inspection with NIL Adverse Observation for the Record Fourth Consecutive Time
Apr 20, 2026
Gurugram (Haryana) [India], April 20: Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced the successful completion of a USFDA (United States Food and Drug Administration) inspection at its Masulakhanna (Himachal) facility, with Zero adverse observations (No Form 483 issued by the drug regulator). This marks the Fourth consecutive NIL 483 USFDA inspection for Morepen over the past eight years.
Read More...
